ACTUALITES SUR LES SYNDROMES CORONARIENS CHRONIQUES



Gilles Montalescot

Pr. Montalescot reports research funds for the Institution or fees from Abbott, Amgen, AstraZeneca, Axis, Bayer, BMS, Boehringer-Ingelheim, Boston-Scientific, Cell Prothera, CSL Behring, Idorsia, Leo-Pharma, Lilly, Medtronic, Novartis, Pfizer, Quantum Genomics, Sanofi, Terumo













www.action-groupe.org




MALADIE CORONAIRE (2000-2020)





METAANALYSIS 11 studies

COURAGE




Katritsis DG et al. *Circulation*. 2005;111:2906-12

Boden et al. *N Engl J Med* 2007;35:1503-16

R Al-Lame et al. Lancet 2018

BARI 2D

Later studies




ORBITA



ISCHEMIE (2020)









Clinical and Stress Test Eligibility Criteria

Inclusion Criteria

- Age ≥21 years
- Moderate or severe ischemia*
 - Nuclear ≥10% LV ischemia (summed difference score ≥7)
 - Echo ≥3 segments stress-induced moderate or severe hypokinesis, or akinesis
 - CMR
 - Perfusion: ≥12% myocardium ischemic, and/or
 - Wall motion: ≥3/16 segments with stress-induced severe hypokinesis or akinesis
 - Exercise Tolerance Testing (ETT) ≥1.5mm ST depression in ≥2 leads or ≥2mm ST depression in single lead at <7 METS, with angina

Major Exclusion Criteria

- NYHA Class III-IV HF
- Unacceptable angina despite medical therapy
- EF < 35%
- ACS within 2 months
- PCI or CABG within 1 year
- eGFR <30 mL/min or on dialysis



Physicians need to understand eligibility and exclusion criteria to determine high risk patients to whom the results of the trial cannot be applied.

*Ischemia eligibility determined by sites. All stress tests interpreted at core labs.

CCTA Eligibility Criteria


Inclusion Criteria

- ≥50% stenosis in a major epicardial vessel (stress imaging participants)
- ≥70% stenosis in a proximal or mid vessel (ETT participants)

Major Exclusion Criteria

≥50% stenosis in unprotected left main

1°EP: CV death, MI, hospitalization for UA, HF or resuscitated cardiac arrest)



Maron DJ, et al. N Engl J Med 2020;382:1395-407.


Group

MI

Myocardial Infarction



Procedural MI *Type 4a or 5 MI* Spontaneous MI Types 1, 2, 4b, or 4c MI



Various definitions of MI




6

38

23

11




Adjusted risk of type 1 MI on CV death HR (95% CI) = 3.38 (2.03, 5.61), P<0.001 Adjusted risk of type 1 MI on CV death HR (95% CI) = 3.52 (2.11, 5.88), P<0.001

Type 1 MI events were associated with subsequent CV death.


Revascularization







Improvement in QoL is related to baseline symptoms



Spertus J et al NEJM 2020

CTION Group



□ ISCHEMIA enrolled stable, low risk, normal EF patients


- □ 4 different imaging modalities
- Selection bias
- Improvement in QOL in patients with significant symptoms
- Likely decline in future use of stress testing vs CTA/FFR
- □ Is Ischemia the right target? Or just one marker?



VIABILITY (2022)

CABG for ischaemic cardiomyopathy







Velazquez EJ et al, NEJM 2016; 374:1511–20

PCI for ischemic cardiomyopathy





Death or Hosp. for HF (1°EP)




Perera D et al, NEJM 2022

Group

3 differences (all expected!)



33 (87%)



Spontaneous MI

18 (49%)

Comments on ISCHEMIA REVIVED


□ ISCHEMIA REVIVED enrolled stable, low risk, normal EF patients

- □ 4 different imaging modalities
- Selection bias
- Improvement in QOL in patients with significant symptoms
- □ Likely decline in future use of stress imaging testing vs CTA/FFR
- □ Is Ischemia viability the right target? Or just one marker?

The Enduring Legacy of Failed Revascularization Trials*

Harold L. Dauerman, MD,^a Jan G.P. Tijssen, PhD,^b Gilles Montalescot, MD, PhD^c

https://doi.org/10.1016/j.jacc.2021.08.059




Beyond ischaemia: is there a place for physiologic and anatomic evaluations of coronary lesions?

Eurointervention 2021

Gilles Montalescot*, MD, PhD ; Michel Zeitouni, MD

Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France



Eye of the cardiologist: - COMPLETE trial - PRAMI trial

- CULPRIT trial

Detailed anatomical evaluation:

- SYNTAX score
- Residual SYNTAX score after primary PCI

FFR before discharge: - DANAMI-3–PRIMULTI - FLOWER-MI (ongoing)

Non-hyperaemic pressure ratios (iFR, RFR...): - More data needed Functional measures (QFR) - More data needed

Current guidelines



Extent of CAD (anatomical and/or functional)			Level
For prognosis	Left main disease with stenosis >50%	1	А
	Proximal LAD stenosis >50%	1	А
	Two- or three-vessel disease with stenosis >50% with impaired LV function (LVEF ≤35%)	I.	А
	Large area of ischaemia detected by functional testing (>10% LV) or abnormal invasive FFR	I.	В
	Single remaining patent coronary artery with stenosis >50%	I.	С
For symptoms	Haemodynamically significant coronary stenosis ^c in the presence of limiting angina or angina equiva lent, with insufficient response to optimized medical therapy		A

Suggestion



Extent of CAD (anatomical and/or functional)			Class	Level
For prognosis	Left main disease with stenosis >50%	I	А	
	Proximal LAD stenosis >50%	I	А	
	Two- or three-vessel disease with stenosis >50% with impaired LV function (LVEF ≤35%)	I	А	
	Large area of ischemia detected by functional testing (>10% LV) or abnormal invasive FFR		В	
		Single remaining patent coronary artery with stenosis >50%	I	С
For sympto	s	Hemodynamically significant coronary stenosis ^c in the presence of limiting angina or angina equivalent, with insufficient response to optimized medical therapy	I	А

Ischemia alone or in combination with other high-risk features




Neumann ESC/EACTS Guidelines, 2019


A Multi-Biomarker Score for a Global Approach of Risk

Time for a Change?*

Gilles Montalescot, MD, PHD,^a Paul Guedeney, MD,^a Jan Tijssen, MD, PHD^b

https://doi.org/10.1016/j.jacc.2022.06.018








In practice?









Conclusions / CCS management

